Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 145

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 145
---
ITEM 4. INFORMATION ON THE COMPANY

A. History and Development of the Company

We were established on June
10, 2015 as a Swiss limited company. Our registered office is located at The Circle 6, Postfach, 8058 Zurich, Switzerland.

In 2016, we acquired several
patents from Assistance Publique - Hopitaux de Paris, or AP-HP, in France, including for our lead compound mazindol. Since our founding,
we have assembled an experienced leadership team with a track record of developing and repurposing products to treat rare neurological
disorders. Our Chief Executive Officer, Alexander Zwyer, has held a variety of senior leadership roles of increasing responsibility in
the pharmaceutical industry, including global roles in business development, sales and marketing, medical as well as regulatory affairs,
and general management. We complement our management team with a group of scientific and clinical advisors that includes internationally
recognized North American and European experts in CNS disorders, including the areas of our current focus, rare hypersomnolence (specifically,
narcolepsy) and complex neurodevelopmental disorders.

Our principal executive offices
are located The Circle 6, Postfach, 8058 Zurich, Switzerland, our general telephone number is (+41) 44 512 21 50 and our internet address
is www. nlspharma. com. The SEC also maintains an internet website that contains reports, proxy and information statements, and other information
regarding issuers that file electronically with the SEC. Our filings with the SEC are available to the public through the SEC’s
website at www. sec. gov. The information contained on our website and the SEC website or available through such websites is not incorporated
by reference into and should not be considered a part of this annual report, and the references to websites in this annual report are
inactive textual references only.

We are an EGC. As such, we
are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable to other public companies
that are not “emerging growth companies” such as not being required to comply with the auditor attestation requirements of
Section 404 of the Sarbanes-Oxley Act. We could remain an EGC for up to five years, or until the earliest of (a) the last day of the first
fiscal year in which our annual gross revenues exceeds $1.235 billion, (b) the date that we become